Corrigendum to "How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain": [ESMO Open, 7 (2022) 100462]
- PMID: 35644100
- PMCID: PMC9156986
- DOI: 10.1016/j.esmoop.2022.100504
Corrigendum to "How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain": [ESMO Open, 7 (2022) 100462]
Erratum for
-
How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain.ESMO Open. 2022 Apr;7(2):100462. doi: 10.1016/j.esmoop.2022.100462. Epub 2022 Apr 6. ESMO Open. 2022. PMID: 35397431 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
